Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HLVX Stock Forecast 2026-2027
$2.09
Current Price
$104.76M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to HLVX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
HLVX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+10.0%
1 Year Change
0.0%
Year-to-Date Change
-3.7%
From 52W High of $2.17
+56.0%
From 52W Low of $1.34
📊 TOP ANALYST CALLS
Did HLVX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if HilleVax is one of their latest high-conviction picks.
Latest HLVX Stock Price Targets & Analyst Predictions
HLVX has shown a year-to-date change of 0.0% and a 1-year change of 10.0%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for HLVX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HLVX Analyst Ratings
0
Buy
1
Hold
0
Sell
HLVX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.09
Latest HLVX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HLVX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Jul 9, 2024 | Leerink Partners | David Risinger | Market Perform | Downgrade | $2.00 |
| Jul 9, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Downgrade | $N/A |
| Jul 9, 2024 | Stifel | Stephen Willey | Hold | Downgrade | $3.00 |
| Jul 8, 2024 | JP Morgan | Eric Joseph | Neutral | Downgrade | $N/A |
| Jul 8, 2024 | Guggenheim | Seamus Fernandez | Neutral | Downgrade | $N/A |
| May 15, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $24.00 |
| May 10, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $28.00 |
| Mar 21, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $28.00 |
| Dec 13, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $28.00 |
| Nov 15, 2023 | Guggenheim | Seamus Fernandez | Buy | Maintains | $34.00 |
| Nov 10, 2023 | Stifel | Stephen Willey | Buy | Maintains | $30.00 |
| May 16, 2023 | JP Morgan | Eric Joseph | Overweight | Maintains | $22.00 |
| May 24, 2022 | SVB Leerink | David Risinger | Outperform | Initiates | $30.00 |
| May 24, 2022 | JP Morgan | Eric Joseph | Overweight | Initiates | $24.00 |
| May 24, 2022 | Stifel | Stephen Willey | Buy | Initiates | $34.00 |
| May 24, 2022 | Guggenheim | Seamus Fernandez | Buy | Initiates | $40.00 |
| Mar 2, 2021 | Morgan Stanley | Overweight | Upgrade | $N/A |
HilleVax, Inc. (HLVX) Competitors
The following stocks are similar to HilleVax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HilleVax, Inc. (HLVX) Financial Data
HilleVax, Inc. has a market capitalization of $104.76M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -40.3%.
Valuation Metrics
Market Cap
$104.76M
Enterprise Value
$-32,557,612
P/E Ratio
-0.7x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+154.2%
Current Ratio
26.4x
Debt/Equity
15.9x
ROE
-40.3%
ROA
-14.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
HilleVax, Inc. (HLVX) Business Model
About HilleVax, Inc.
What They Do
Develops and commercializes vaccines for infectious diseases.
Business Model
HilleVax Inc. focuses on advancing vaccine candidates to address significant unmet medical needs, generating revenue through the development and commercialization of these innovative solutions. By targeting diseases that affect a wide range of populations, the company aims to penetrate the healthcare market and contribute to public health.
Additional Information
Operating in the specialized field of vaccine technology, HilleVax leverages expertise in virology and immunology. The company's progress in developing preventive healthcare measures has the potential to significantly influence the global vaccine market and attract investments from those interested in transformative healthcare solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Dr. Robert M. Hershberg M.D., Ph.D.
Country
United States
IPO Year
2022
Website
www.hillevax.comHilleVax, Inc. (HLVX) Latest News & Analysis
Latest News
Quick Summary
Kahn Swick & Foti is investigating HilleVax's proposed sale to XOMA, offering $1.95 per share plus contingent value rights, to assess if the deal adequately values the company.
Why It Matters
The investigation into HilleVax's sale may indicate potential undervaluation, impacting shareholder returns and altering market perceptions of the company's worth and future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for potential fiduciary duty breaches related to its deal with XOMA Royalty Corporation, where shareholders will receive $1.95 per share in cash.
Why It Matters
HilleVax's potential breaches of fiduciary duty during its transaction with XOMA Royalty could impact shareholder value and lead to legal repercussions, affecting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
HilleVax, Inc. reported Q2 2025 financial results, showing cash and equivalents of $159.5 million, down from $171.4 million at the end of 2024.
Why It Matters
HilleVax's cash position declined, which may impact its ability to fund ongoing vaccine development, influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)
9 months ago
Quick Summary
Monteverde & Associates PC is investigating HilleVax, Inc. (NASDAQ: HLVX) regarding its sale to XOMA Royalty Corporation. The firm is recognized for recovering millions for shareholders.
Why It Matters
The investigation into HilleVax's sale could signal potential legal risks or financial implications, impacting shareholder value and market perception of HLVX.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rowley Law PLLC is investigating HilleVax, Inc. (NASDAQ: HLVX) for potential securities violations related to its acquisition by XOMA Royalty Corporation (NASDAQ: XOMA), offering $1.95 per share plus contingent rights.
Why It Matters
The investigation into HilleVax's acquisition may signal potential legal risks or valuation issues, impacting shareholder confidence and stock price volatility.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
HilleVax, Inc. is proposed to be sold to XOMA Royalty Corporation for $1.95 per share in cash, plus a contingent value right for additional payments.
Why It Matters
The investigation into HilleVax's proposed sale could signal risks or potential changes in the deal, impacting shareholder value and market perception of both companies.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About HLVX Stock
What is HilleVax, Inc.'s (HLVX) stock forecast for 2026?
Analyst forecasts for HilleVax, Inc. (HLVX) are not currently available. The stock is trading at $2.09.
Is HLVX stock a good investment in 2026?
According to current analyst ratings, HLVX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HLVX stock?
Price predictions from Wall Street analysts for HLVX are not currently available. The stock is trading at $2.09.
What is HilleVax, Inc.'s business model?
HilleVax Inc. focuses on advancing vaccine candidates to address significant unmet medical needs, generating revenue through the development and commercialization of these innovative solutions. By targeting diseases that affect a wide range of populations, the company aims to penetrate the healthcare market and contribute to public health.
What is the highest forecasted price for HLVX HilleVax, Inc.?
Price targets from Wall Street analysts for HLVX are not currently available. The stock is trading at $2.09.
What is the lowest forecasted price for HLVX HilleVax, Inc.?
Price targets from Wall Street analysts for HLVX are not currently available. The stock is trading at $2.09.
What is the overall HLVX consensus from analysts for HilleVax, Inc.?
The overall analyst consensus for HLVX is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are HLVX stock price projections?
Stock price projections, including those for HilleVax, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 7, 2026 9:03 AM UTC